VHL Ligand 38
VHL Ligand 38 (Compound 1) is a competitive E3 ubiquitin-protein ligase VHL inhibitor with IC50s of 4.1 and 7.0 μM in 1% and 10% DMSO, respectively. VHL Ligand 38 contains a hydroxyproline residue and an isoxazolylacetamide fragment. VHL Ligand 38 significantly inhibits the binding of a fluorescent peptide derived from HIF1α (FAM-DEALA-Hyp-YIPD) to VHL[1].
Product Specifications
CAS Number
1360616-29-0
UNSPSC
12352005
Target
E1/E2/E3 Enzyme
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Others
Smiles
O=C([C@H]1N(C(CC2=CC(C)=NO2)=O)C[C@H](O)C1)NCC3=CC=C(C4=CN=CO4)C=C3
Molecular Formula
C21H22N4O5
Molecular Weight
410.42
References & Citations
[1]Buckley DL, et al. Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α. Angew Chem Int Ed Engl. 2012 Nov 12;51 (46) :11463-7.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TL318406V 500 µL Each
FLJ26056 Human shRNA Lentiviral Particle (Locus ID 375127)
Sign In for Pricing
View Details orb2704003-01 1 mg
Sofituzumab Biosimilar (MUC16 Reference Antibody)
Sign In for Pricing
View Details orb2704003-02 5 mg
Sofituzumab Biosimilar (MUC16 Reference Antibody)
Sign In for Pricing
View Details orb2704003-03 100 mg
Sofituzumab Biosimilar (MUC16 Reference Antibody)
Sign In for Pricing
View Details 